Insulin patch pumps are small, wearable devices that deliver insulin to diabetic patients continuously. They are a relatively new technology that has gained popularity in recent years owing to their ability to provide more accurate and convenient insulin delivery. The insulin patch pumps market has grown rapidly with the increasing diabetic population and technological advancements. According to Inkwood Research, the global insulin patch pumps market is expected to reach $2760.98 million by 2032, growing at a 10.63% CAGR during the forecasted period, 2023 to 2032.
Evolution of Insulin Patch Pumps: Battery-Powered to Automation
According to the National Library of Medicine, in 1976, Dean Kamen designed the first wearable insulin pump, known as the ‘blue brick’ and later as the ‘Autosyringe,’ which facilitated the introduction of insulin pump therapy that same year. In 1979, the first SOOIL insulin pump was clinically evaluated at Seoul National University Hospital. In 1983, MiniMed introduced its first insulin pump, MiniMed 502. This system soon underwent significant improvements in size and programmability and thus represented a major technologic breakthrough in the evolution of insulin pumps.
The new generation external pumps, released in the 1990s, are comparatively compact and effective. These ‘smart pumps’ have features such as built-in bolus calculators, personal computer interfaces, and alarms. The currently popular insulin pump models on the global market are T:Slim from Tandem, Medtronic MiniMed, Accu-Chek Solo Micropump from Roche, OmniPod from Insulet, SOOIL’s DANA R, etc.
Now, toward the advent of Machine Learning and Artificial Intelligence in Diabetes Care:
In the last few years, the healthcare industry has witnessed an unprecedented surge in using machine learning (ML) and artificial intelligence (AI) in medical devices. Insulin patch pumps have been a significant area where these technologies have played crucial roles, including enhanced & efficient care, reduced medical errors, and improved patient outcomes.
Accordingly, major market leaders and medical professionals have welcomed the advent of machine learning and artificial intelligence in insulin patch pumps.
- In March 2020, Companion Medical launched its InPen system, a smart insulin pen that tracks insulin dosages, glucose levels, and carbohydrate intake. The InPen system uses machine learning algorithms to analyze data from continuous glucose monitoring (CGM) systems and provide personalized insulin recommendations.
- In May 2020, Medtronic launched its MiniMed 780G system, an advanced insulin patch pump that uses artificial intelligence to automate insulin dosing. The MiniMed 780G system has a built-in algorithm that adjusts insulin delivery systems based on the patient’s glucose levels, providing more accurate and personalized insulin therapy.
The impact of these devices on the healthcare industry has been significant. Providing precise and efficient insulin delivery has helped reduce the risk of hypoglycemia, improve patient outcomes, and minimize the burden on healthcare providers. Moreover, ML and AI algorithms have the potential to revolutionize the field of diabetes care and pave the way for more personalized and precise treatments.
However, using machine learning and artificial intelligence in insulin patch pumps has also raised data privacy and security concerns. Insulin patch pumps collect a vast amount of sensitive patient data, including glucose levels, insulin dosages, and other health-related information. This data needs to be protected from cyber threats and unauthorized access.
To address these concerns, insulin patch pump manufacturers have implemented strict data privacy policies and taken measures to ensure the security of patient data.
- Companion Medical’s InPen system encrypts patient data and only allows authorized users to access it.
- Medtronic’s MiniMed 780G system has several layers of security, including encryption, authentication, and monitoring, to protect patient data.
Despite these efforts, some experts remain skeptical of using ML and AI in medical devices. Some have raised concerns about the accuracy and reliability of these algorithms and the potential for bias in their decision-making. Others have argued that the use of these technologies could lead to a reduction in the human touch in healthcare, thus undermining the doctor-patient relationship.
What more is in store for the Insulin Patch Pumps Market?
The use of technology to assist those with Type 1 Diabetes has failed to accomplish its ultimate goal of improving glycemic control. However, early results from applying Artificial Intelligence principles for patients under Metered Dose Inhaler (MDI) therapy in the form of Acquired Demyelinating Syndrome (ADS) show the potential to close this gap (Source).
Furthermore, Continuous Glucose Monitoring (CGM) technology and smart pens with Bluetooth capabilities could make incorporating technology easier and reduce patient burden. It is expected that adoption in this field will continue growing in the next few years so that everyone with diabetes can reap the advantages of automation and AI. These factors are expected to boost the global insulin patch pumps market during the forecast period.
What are some key drivers of the global insulin patch pumps market?
The growing prevalence of diabetes among people, technological advancements in the insulin patch pumps, and the rising awareness regarding patch pumps are some key drivers of the global insulin patch pumps market.
Which trends are projected to direct the global insulin patch pumps growth?
The rising occurrence of diabetes, growing healthcare awareness, advances in technology in insulin delivery systems, and growing research and development trends are projected to direct the global insulin patch pumps growth.